• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    京

    京都大学医院

    Kyoto University Hospital
    EST. 1899
    6,219论文总数
    17万引用总数

    论文量&引用量时间轴

    机构学者

    论文(6219)

    年份
    起
    –
    止
    排序
    1Corrigendum to “fast Oscillations As Useful Biomarkers of the Degree of Epileptogenicity in Each Generalized Epilepsy Syndrome” [clin. Neurophysiol. 190 (2026) 2112320]
    Megumi Nonaka,Masao Matsuhashi,Maya Tojima,Miwa Takatani,Shuichiro Neshige,Katsuya Kobayashi,Takeshi Yoshida,Akihiro Shimotake,Kiyohide Usami,Yasuhiro Kojima,Riki Matsumoto,Hirofumi Maruyama,
    2027Clinical Neurophysiology(2027)
    引用
    AI阅读
    加入学术空间
    2Nationwide Implementation and Inter-Institutional Gaps in Care Coordination for Older Adults with Cancer in Japan: A Multi-Sector Survey
    Ayumu Matsuoka, Misaki Ayata, Ryo Yasumaru,Yuichi Ando,Hiroyuki Umegaki, Fumihiko Kanai, Tetsuya Sasaki,Miho Suzuki, Chie Tanaka,Yukari Tsubata,Tomohiro Terada,Fumio Nagashima,

    Introduction: Effective coordination between hospitals and community-based providers is essential to support home-based care for older adults with cancer. We previously identified six key domains of effective coordination-system infrastructure, information exchange, communication, timeliness, human resource development, and information dissemination-highlighting anticipatory and relational elements. However, their nationwide implementation across care settings remains unclear. This study aimed to clarify the implementation status of coordination practices across these domains and to identify inter-institutional gaps among hospitals and community-based providers. Materials and methods: We conducted a nationwide cross-sectional survey (July-September 2025) targeting all designated cancer care hospitals (DCHs; n = 463), randomly selected home visit medical facilities (HVMFs; n = 1500), and long-term care management agencies (LTCMAs; n = 1500). Implementation of Best Practice items was assessed using a 5-point Likert scale. Rates >= 75% were classified as Higher Implementation and <75% as Lower Implementation; differences of >= 20% were defined as inter-institutional gaps. Results: A total of 1156 institutions responded (209 DCHs, 315 HVMFs, and 632 LTCMAs; response rate 33.4%). Across domains, implementation was higher for system infrastructure and information exchange related to discharge and inpatient care, whereas communication, timeliness, human resource development, and information dissemination were lower, particularly in outpatient and anticipatory phases. Discharge-or crisis-triggered processes, including standardized documentation, inpatient biomedical information exchange, and urgent communication, were classified as Higher Implementation. In contrast, outpatient-phase coordination, sharing of advance care planning (ACP) and contextual information, information and communication technology (ICT)enabled bidirectional communication, post-transition feedback, workforce development, and patient-facing information dissemination were classified as Lower Implementation. Inter-institutional gaps >20% were common at the hospital-community interface, especially between DCHs and LTCMAs in ACP and contextual information sharing, and between DCHs and HVMFs in ICT-based communication and post-transition feedback. Discussion: While discharge and crisis-response coordination for older adults with cancer in Japan is well-established, gaps remain in anticipatory, contextual, and bidirectional domains. These findings suggest that management for this population, which requires integration of oncologic, functional, and psychosocial care, is predominantly transition-triggered rather than trajectory-based. In aging societies such as Japan, strengthening anticipatory engagement and relational integration across medical and long-term care sectors will be critical to achieving person-centered home-based cancer care.

    2027JOURNAL OF GERIATRIC ONCOLOGY(2027)
    引用
    AI阅读
    加入学术空间
    3Analytical and Clinical Validation of Ion Torrent™ Oncomine™ Dx Express Test for Identifying
    Charlotte Elvidge, Macy Heung,Thomas Clark,Coumaran Egile,Scott Myrand,Corey Russo,Gaia Schiavon, Shoko Shibata, Amy Spencer,Masakazu Toi,Anne Marie Velasco Roth,John Williamson,

    This study reports on analytical and clinical validation of the highly automated Ion Torrent™ Oncomine™ Dx Express Test (ODxET) for detecting PIK3CA / AKT1 / PTEN -altered tumors in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer that may benefit from treatment with capivasertib plus fulvestrant. Analytical validation studies were completed using commercially sourced breast cancer tissue specimens to establish the ODxET assay detection capability (limit of detection, limit of blank), precision (repeatability, reproducibility), and effect of endogenous interfering substances for detecting PIK3CA / AKT1 / PTEN alterations. Clinical validation was performed using 429 residual breast cancer tissue samples from the Phase 3 CAPItello-291 trial and progression-free survival (PFS) was analyzed for patients with PIK3CA / AKT1 / PTEN -altered tumors, as detected by ODxET, and compared to efficacy outcomes from the CAPItello-291 study. Comparison of assay agreement between ODxET and FoundationOne®CDx (F1CDx) gave an overall, positive and negative percent agreement of 89.2%, 82.0%, and 96.6%, respectively. The 18% false negative rate observed with ODxET was largely attributable to limited detection of complex PTEN variants. PFS benefit was observed with capivasertib plus fulvestrant versus placebo plus fulvestrant in patients with PIK3CA / AKT1 / PTEN -altered tumors detected by ODxET ( n =162; hazard ratio 0.55, 95% confidence interval [CI]: 0.38–0.78). This is similar to the observed PFS benefit in the population with PIK3CA / AKT1 / PTEN -altered tumors identified by F1CDx in the CAPItello-291 trial (hazard ratio 0.49, 95% CI: 0.38–0.64). This study demonstrates the clinical utility of ODxET to identify patients with PIK3CA / AKT1 / PTEN -altered tumors that may benefit from treatment with capivasertib plus fulvestrant.

    2027Translational Oncology(2027)
    引用
    AI阅读
    加入学术空间
    4Analytical and Clinical Validation of Ion Torrent™ Oncomine™ Dx Express Test for Identifying PIK3CA/AKT1/PTEN-altered Tumors in Patients with Hormone Receptor-Positive Advanced Breast Cancer for Treatment with Capivasertib
    Charlotte Elvidge, Macy Heung,Thomas Clark,Coumaran Egile,Scott Myrand,Corey Russo,Gaia Schiavon, Shoko Shibata, Amy Spencer,Masakazu Toi,Anne Marie Velasco Roth,John Williamson,

    This study reports on analytical and clinical validation of the highly automated Ion Torrent™ Oncomine™ Dx Express Test (ODxET) for detecting PIK3CA/AKT1/PTEN-altered tumors in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer that may benefit from treatment with capivasertib plus fulvestrant.Analytical validation studies were completed using commercially sourced breast cancer tissue specimens to establish the ODxET assay detection capability (limit of detection, limit of blank), precision (repeatability, reproducibility), and effect of endogenous interfering substances for detecting PIK3CA/AKT1/PTEN alterations. Clinical validation was performed using 429 residual breast cancer tissue samples from the Phase 3 CAPItello-291 trial and progression-free survival (PFS) was analyzed for patients with PIK3CA/AKT1/PTEN-altered tumors, as detected by ODxET, and compared to efficacy outcomes from the CAPItello-291 study.Comparison of assay agreement between ODxET and FoundationOne®CDx (F1CDx) gave an overall, positive and negative percent agreement of 89.2%, 82.0%, and 96.6%, respectively. The 18% false negative rate observed with ODxET was largely attributable to limited detection of complex PTEN variants. PFS benefit was observed with capivasertib plus fulvestrant versus placebo plus fulvestrant in patients with PIK3CA/AKT1/PTEN-altered tumors detected by ODxET (n=162; hazard ratio 0.55, 95% confidence interval [CI]: 0.38–0.78). This is similar to the observed PFS benefit in the population with PIK3CA/AKT1/PTEN-altered tumors identified by F1CDx in the CAPItello-291 trial (hazard ratio 0.49, 95% CI: 0.38–0.64). This study demonstrates the clinical utility of ODxET to identify patients with PIK3CA/AKT1/PTEN-altered tumors that may benefit from treatment with capivasertib plus fulvestrant.

    2027Translational Oncology(2027)
    引用
    AI阅读
    加入学术空间
    5Definitive Radiotherapy for Non-Small-cell Lung Cancer: Current Practice and Future Directions
    Noriko Kishi,Tomoki Kimura,Takashi Mizowaki

    Lung cancer is one of the malignancies for which new clinical evidence has accumulated most rapidly in recent years. In parallel with advances in systemic therapy, radiotherapy has also evolved substantially with the development of high-precision techniques such as stereotactic body radiotherapy (SBRT), intensity-modulated radiotherapy, and particle therapy. These technological innovations, together with the introduction of immunotherapy and targeted therapies, have reshaped the role of radiotherapy within multidisciplinary treatment strategies for non-small cell lung cancer (NSCLC). This review summarizes current clinical practice and emerging perspectives in radiotherapy for NSCLC across disease stages. In early-stage disease, the established role of SBRT and the potential advantages of particle therapy as curative strategies for medically inoperable patients and for operable patients who refuse surgery are outlined. For locally advanced NSCLC, evolving treatment paradigms in the era of immunotherapy are reviewed, including concurrent chemoradiotherapy followed by consolidation immunotherapy, as well as ongoing efforts to reduce treatment-related toxicity through advances in radiotherapy techniques. In addition, the emerging role of radiotherapy as local consolidative therapy for oligometastatic stage IV NSCLC is highlighted, with attention to recent randomized trials and the challenges of patient selection. As treatment strategies for NSCLC continue to evolve rapidly, radiotherapy is expected to play an increasingly important role in multidisciplinary management. Further research is required to optimize treatment sequencing, identify patients most likely to benefit from radiotherapy, and refine its integration with modern systemic therapies. Radiotherapy remains a key component of multidisciplinary management for non-small cell lung cancer (NSCLC). This review summarizes current clinical evidence and the evolving roles of radiotherapy across disease stages, including early-stage, locally advanced, and oligometastatic NSCLC.

    2026Japanese Journal of Radiology(2026)引用:77
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 6219 篇论文

    合作机构(100)

    京都大学合作论文 2,083
    东京大学合作论文 196
    京都府立医科大学合作论文 149
    大阪大学合作论文 141
    Kobe City Medical Center General Hospital合作论文 119
    九州大学合作论文 117
    筑波大学合作论文 112
    倉敷中央病院合作论文 108
    广岛大学合作论文 100
    庆应义塾大学合作论文 100

    机构统计